Benzinga Quick Stats: Merus IPO

Merus BV MRUS is an immuno-oncology company that develops antibody therapeutics.

Initial range for 4.33 million shares at $14-$16/share

Morning of the IPO cut the price to $10

Shares opened for trade at $9.75

Spiked to $10.73, but fell to $10.04 by market close

On Friday, shares were up about 1 percent at $10.16 about three hours into trading.

Biotech IPOs have struggled lately.

NovoCure Limited NVCR debuted last fall at $22/share and fell 17 percent the day after. On Thursday, NovoCure closed at $11.60.

MyoKardia, Inc. MYOK initially priced their shares at $15-$17, revised that to $10 the day before the offering happened, and now sits at $12.11 as of Thursday.